---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-286870"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2021-09-29T23:59:59+00:00"
generated_at: "2026-06-29T00:41:03.921428+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Coherus BioSciences announces passing of board member Dr. Samuel Nussbaum

## Summary
- Dr. Samuel Nussbaum passed away on September 23, 2021.
- He had served as a director of Coherus since May 2018.
- CEO Denny Lanfear expressed gratitude for Dr. Nussbaum's guidance and support.
- Dr. Nussbaum was former EVP, Chief Medical Officer at Anthem from 2000 to 2016.

## SEC filing metadata
- accession: 0001193125-21-286870
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2021-09-29T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000119312521286870/0001193125-21-286870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000119312521286870/d119636d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-286870
- JSON: https://secwatch.observer/filing/0001193125-21-286870.json
- Plain text: https://secwatch.observer/filing/0001193125-21-286870.txt

## Key facts
- Executive change
  Samuel Nussbaum departed as Member of the Board of Directors at Coherus Oncology, Inc..
  - Action: passed away
  - Role: Member of the Board of Directors
  source text: Samuel Nussbaum, M.D., a member of the Company’s Board of Directors, passed away on Thursday, September 23, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000119312521286870/0001193125-21-286870-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.